Peptide Secrets

Guide 01

What Peptides Actually Are: The Plain-English Map Before You Buy a Vial

Start here

Seven different things the single word peptide can honestly describe, laid out in one table with who is accountable for each.
Why insulin and teriparatide sit in a different world from a code-numbered vial.
Nine facts that belong on one page first, from the exact substance name to what would count as no benefit.

Guide 02

Am I Fit for Peptides? Goals, Health History, and "Don't Touch This Yet" Signals

Fit and eligibility

The one-page history a clinician actually weighs: conditions, medicines, allergies, pregnancy context, cancer history.
Why an established path that was never tried is itself an answer to the fitness question.
Three signals that mean not this year, and who is qualified to decide which one applies.

Guide 03

Who Peptides May Help: Recovery, Sleep, Skin, Metabolic, and Performance Buckets

Five buckets

Recovery, sleep, skin, metabolic and performance, each graded by the state of published human evidence.
Which bucket has approved medicines with labels, and which rest largely on preclinical work.
How to write your complaint in one sentence a clinician would recognize, using no category name.

Guide 04

Who Peptides Are Not For: Red Flags to Discuss Before You Start Experimenting

Red flags

Hard clinical stops sorted apart from the flags that only call for a conversation first.
Why pregnancy context, cancer history and growth signaling each get their own branch in the decision path.
What an approved peptide label prints at the very top, and what that record was built from.

Guide 05

The Peptide Map: BPC-157, TB-500, CJC/Ipamorelin, GHK-Cu, GLP-1s, and What Each Is Supposed to Do

The compounds

BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu and GLP-1s placed side by side on one status map.
Which of the six carry an approved human indication, and what FDA has written about each of the rest.
How to place a compound you have never heard of onto the same map, by route and by status.

Guide 06

Prescription, Clinic, Compounding Pharmacy, or Research Chemical? The Access Paths Explained

Access routes

Four doors with four accountable parties: approved drug, 503A pharmacy, 503B facility, research chemical.
What FDA states about who verifies safety, effectiveness and quality for a compounded product, and who does not.
Registered, inspected and approved are three different words. One paragraph separates them.

Get Peptide Secrets

Guide 07

The Evidence Ladder: Which Peptides Have Human Data and Which Are Mostly Hype

Evidence rungs

Seven rungs from mechanism to controlled trial, each with what it can settle and what it cannot.
Four questions that turn "studies show" into something checkable: what species, how many, how long, against what.
Why a compound that quietly reached rung six is the one you miss by dismissing the whole field.

Guide 08

The Legal Gray Zone: What "Research Use Only" Really Means for Buyers

Research use only

What the phrase "research use only" commits the person who printed it to, and what it never transfers.
Four regulatory buckets, and the obligation each one places on somebody by name.
How the same molecule can sit in every bucket at once, and how to tell which one you are holding.

Guide 09

The Quality Problem: COAs, Sterility, Storage, and the Ways Bad Vials Burn People

Quality documents

Purity, sterility and endotoxin are three separate questions. A certificate of analysis answers one.
Whether the lot number on your vial appears on the document you were shown, and what follows if it does not.
Which of the three real risks a chromatogram speaks to, and which two it leaves completely untouched.

Guide 10

The Peptide Consult Checklist: Questions to Ask Before You Say Yes

The appointment

One question built to produce a no: what would make you tell me not to do this?
Questions sorted by job: what the product is, whether you are a candidate, what happens afterward.
What oversight looks like on paper, a named responsible party, a monitoring interval, a written stop rule.

Guide 11

Baseline Labs and Health History: What to Know Before Any Peptide Plan

Baseline data

Two jobs a baseline does, and why only one of them is ever discussed out loud.
Markers chosen to inform a decision, next to markers chosen to make a panel look thorough.
What "normal but not optimal" would have to mean before it could mean anything at all.

Guide 12

Storage, Handling, and Label Literacy: The Boring Details That Actually Matter

Reading labels

What an approved label commits somebody to: established name, strength, lot, date, storage statement, maker.
FDA has required expiration dating since 1979. Who sets a beyond-use date is a separate question.
Which storage words carry an external standard: lyophilized, bacteriostatic, pharmaceutical grade, under nitrogen.

Get Peptide Secrets

Guide 13

Side Effects and Stop Signals: When to Pause and Call a Professional

Stop signals

Symptom classes sorted by how fast each one moves, because urgency is the decision you have to get right tonight.
How to tell injection site irritation from an infection that needs attention.
What to write down so a clinician can act: exact product, its labeling, everything else started that week.

Guide 14

Injury and Recovery Peptides: BPC-157, TB-500, and the Claims Around Tissue Repair

Tissue repair

The gap between pain relief and tissue repair, and which one a recovery timeline is actually promising.
Where BPC-157 and TB-500 come from: a gastric juice sequence and a thymosin beta-4 fragment.
What standard care predicts over three months, and how to tell genuinely behind from merely slow.

Guide 15

Sleep and Growth-Hormone Secretagogues: CJC, Ipamorelin, Tesamorelin, and the Tradeoffs

GH secretagogues

Tesamorelin, CJC-1295 and ipamorelin are not one product with three names, and a status table shows why.
Four tradeoffs a sleep label leaves out: glucose, fluid retention, tumor history, anti-doping exposure.
Why sleep apnea belongs in the sequence ahead of any growth hormone axis conversation.

Guide 16

Skin, Hair, and Copper Peptides: GHK-Cu Without the Beauty-Influencer Fog

Copper peptides

FDA's rule in one line: intended use, not the ingredient, decides whether a jar is a cosmetic or a drug.
Ingredient research and finished-product evidence are two separate files, and only one of them exists here.
Which scalp and skin changes deserve a medical look before any bottle joins the shelf.

Guide 17

Metabolic Peptides: Where GLP-1s Fit and What Else Is Chasing the Same Promise

Metabolic shelf

Five regulatory situations hiding under one word: approved, compounded, altered, investigational, unlabeled.
What MedlinePlus lists semaglutide injection as actually being used for, quoted in full.
The difference between sharing a pathway and having demonstrated an outcome in people.

Guide 18

The Peptide Stack Problem: Why More Compounds Usually Means More Confusion

Stack problem

Why three compounds at once costs you the ability to learn anything.
The one-at-a-time rule, and the review date that has to be set before a second vial is opened.
Which variable to isolate first, and the dated log that makes the answer readable later.

Get Peptide Secrets

Guide 19

Cycling, Tolerance, and Breaks: What People Track When Effects Fade

When effects fade

Six candidate explanations for a fading effect, and how few of them a break would ever address.
Degradation, lot variation, immune response, a shifting hormonal axis, or a life that changed around the experiment.
Why tachyphylaxis used correctly in a sentence is still not a finding about you.

Guide 20

The Results Dashboard: Pain, Sleep, Body Composition, Labs, and Subjective Traps

Results tracking

Pain, sleep, body composition, and labs, recorded so they still mean something later.
Subjective traps that make a placebo look like a result.
What to write down on day one so that month three is readable.

Guide 21

12 Peptide Myths That Make Beginners Easy to Sell

Twelve myths

Every myth tested by one question: what did believing this let you stop asking?
Twelve claims sorted into six shapes, so the filter still works on a myth this list never named.
Why a myth lands at the moment of relief rather than the moment of doubt.

Guide 22

The Next Peptide Wave: Oral Peptides, Obesity Clinics, Recovery Clinics, and What to Watch

What comes next

Novelty is a claim about the calendar. The status rows are what decide who can be held responsible.
Orforglipron reaching approval in 2026, as a worked example of new arriving through the front door.
How to run the same status filter next quarter, on a compound this collection never named.

Guide 23

Tendon Pain and Peptide Claims: What BPC-157 and TB-500 Can and Cannot Promise

Tendon evidence

Five clinical studies of BPC-157 counted by FDA, all in inflammatory bowel disease, none in a tendon.
Red flags for a tendon that cannot wait: a sudden pop, a gap you can feel, loss of function.
What progressive loading under clinical supervision looks like, and the review date that belongs with it.

Guide 24

The Joint-Pain Peptide Pitch: Inflammation, Recovery, and the Evidence Gap

Joint pain

Four causes of joint ache that announce themselves identically and call for different care.
What FDA recorded for KPV, BPC-157 and the compound sold as LL-37, absence by absence.
Why one hot, swollen joint arriving with fever outranks every other page in the chapter.

Get Peptide Secrets

Guide 25

Peptides for Poor Sleep: Recovery Claims, Hormone Tradeoffs, and Better Questions

Sleep claims

Emideltide has human sleep data: six people, three nights, an intravenous line, published in 1981.
FDA on epitalon, in one sentence: no clinical data support its safety when used in humans.
Why the American College of Physicians names a therapy, not a pill, as the first step for chronic insomnia.

Guide 26

The Brain-Fog Peptide Guide: Semax, Selank, Focus Claims, and Missing Evidence

Focus claims

Semax is registered in Russia as nasal drops, and that registration does not cross a border.
Three uses the Semax nomination actually named: cerebral ischemia, migraine, trigeminal neuralgia.
Sudden confusion, speech trouble or one-sided weakness: the short list that outranks the chapter.

Guide 27

Low Energy and Mitochondrial Peptides: MOTS-c, Humanin, and the Hype Check

Fatigue and energy

FDA on MOTS-c: no human exposure data identified, by any route, anywhere in its literature search.
Why measuring the humanin a body already makes is a different study from giving humanin to someone.
Fatigue with chest pain, breathlessness at rest, night sweats or a new lump: the list that comes first.

Guide 28

Skin Aging and Collagen Peptides: GHK-Cu, Topicals, Injections, and Realistic Outcomes

Skin and collagen

FDA draws its line through the word wrinkle by intended use, and that line decides the whole category.
What a 2025 Bioimpacts review found for topical GHK, and what it recorded sitting right beside it.
Where the injectable form of those same three letters sits on FDA's flagged-substances list.

Guide 29

Hair-Loss Peptides: Copper Peptides, Growth Claims, and What Else to Rule Out

Hair loss

Two approved drugs clear FDA's bar for pattern hair loss, and neither one of them is a peptide.
The rule-out queue a serum cannot run: thyroid, iron studies, a recent illness, medications, a diet change.
What MedlinePlus says about telogen effluvium's own clock, and why that makes the bottom of the cycle photograph so well.

Guide 30

The Sexual-Health Peptide Guide: PT-141, Expectations, Side Effects, and Clinical Oversight

PT-141 label

PT-141 is bremelanotide, approved as Vyleesi in 2019, and its label is a public document.
The indication in full, plus the three limits the label puts on it in its own Limitations of Use.
Nausea at 40 percent, flushing at 20.3, injection-site reactions at 13.2, each with a denominator.

Get Peptide Secrets

Guide 31

Metabolic Plateaus Beyond GLP-1s: Tesamorelin, AOD-9604, and the Clinic-Sales Filter

Metabolic plateaus

EGRIFTA WR states its indication in a single sentence, and that sentence turns out to be very narrow.
AOD-9604 is the compound here whose human evidence exists and points the other way.
What a plateau review actually covers, and why a stall after months is expected physiology.

Guide 32

Gut and Inflammation Peptides: The Claims, the Unknowns, and the Red Flags

Gut claims

Leaky gut names a mechanism hypothesis, which is the wrong shape for something a clinician writes in a chart.
Five clinical studies of BPC-157 found by FDA, one randomized, and that one exists only as a meeting abstract.
Granted its best reading, that trial still describes a rectal enema given daily for two weeks.

Guide 33

Peptides and Low Testosterone: What the Research Shows

Testosterone claims

The one approved gonadotropin in this category, and the exact indication its DailyMed label names.
A 24-hour kisspeptin-10 infusion study in three healthy men, ages 23 to 32, read at its real size.
Why FDA indication language asks for low levels plus an associated medical condition, not a symptom list.

Guide 34

Peptides and Immune Support: What the Research Shows

Immune claims

ETASS and TESTS: two thymosin alpha-1 sepsis trials, 361 patients then 1,089, landing in opposite places.
A pooled odds ratio of 0.73 across 11 trials, and the four analyses that qualified it.
The distance between an intensive care unit and an ordinary winter, measured rather than assumed.

Guide 35

Peptides and Healing After Surgery: What the Research Shows

After surgery

544 articles screened, 36 included, 35 preclinical, one clinical: the BPC-157 count from HSS Journal.
Twelve knee patients behind that single human study, and what the review recorded about controls.
Wound signals that hand the whole question straight back to the team that operated on you.

Guide 36

Peptides and Workout Recovery: What the Research Shows

Recovery stack

27 randomized growth hormone trials pooled across 440 participants, mean study size fifteen people.
2.1 kilograms of lean mass and soft tissue edema in 44 percent, reported by the same review.
What the NIH Office of Dietary Supplements names as carrying real human evidence for performance.

Get Peptide Secrets

Guide 37

Peptides, Longevity and Aging: What the Research Shows

Longevity claims

The 2025 epitalon review: striking mouse and fly numbers on one side, two open-label human studies on the other.
162 patients with retinitis pigmentosa, over ten days in St Petersburg, the human epitalon record in full.
Growth hormone as the case study, from anti-aging headline of the 1990s to 18 randomized human trials.

Guide 38

Peptides After a GLP-1: What the Research Shows About Keeping Weight Off

After stopping

The STEP 1 extension followed 327 people for a year after the drug stopped, and wrote down what happened.
SURMOUNT-4 at week 88: 25.3 percent on continued tirzepatide against 9.9 percent on placebo.
What tesamorelin's own EGRIFTA SV label states about weight, printed in its Limitations of Use.

Guide 39

Peptides and Back Pain: What the Research Shows

Back pain

Three published human studies of BPC-157 counted by a 2025 review, not one of them about a spine.
Cauda equina signals MedlinePlus flags: loss of bladder or bowel control, new weakness in the saddle area.
Cochrane puts NSAIDs for chronic low back pain at 6.97 points on a 0 to 100 scale, across 1,354 people.

Guide 40

Peptides Without Needles: Oral, Nasal and Topical Routes

No needles

Why a digestive tract takes amino acid chains apart, and the shape shared by the few that survive it.
RYBELSUS puts oral semaglutide at 0.4 to 1 percent bioavailability, with an enhancer and a fasting window.
DDAVP tablets sit near 5 percent of the nasal route, and the label explains how the product still works.

Guide 41

Peptides, Perimenopause and Menopause: What the Research Shows

Menopause claims

KNDy neurons, the vasomotor pathway, and the one drug that actually came out of it in May 2023.
Vyleesi's label names premenopausal women, and this chapter works out what that means after menopause.
Epitalon's single formal human trial: 162 patients with an eye disease, over ten days.

Guide 42

How to Cut Your Peptide Clinic Bill Without Cutting Corners

Clinic bills

503A pharmacy or 503B outsourcing facility, and what that split changes about where a prescription is filled.
A 2024 JAMA Network Open study test-purchased semaglutide from six no-prescription websites. Half produced no drug.
Five moves that lower a bill without lowering the standard, and not one of them is a coupon code.

Everything you need to know about peptides

Ten questions the collection answers.

Your curiosity could be the start of a new chapter.

When curiosity leads to a maze

Now imagine seeing the whole world of peptides unfold

Picture yourself finally feeling part of the conversation

Whatever brought you here, there’s a guide for it.

Low testosterone claims: why symptoms alone cannot confirm it.

Immune-support peptides: which ones have been studied in people.

Peptides sold for surgical healing: one clinical study, thirty-five preclinical.

Workout-recovery peptides: what human studies measured, including for tested athletes.

Longevity peptides: promising ideas versus proven human outcomes.

And that’s only part of the collection.

After a GLP-1 ends: what the extension studies observed.

Peptides sold for back pain: three human studies, none about a spine.

Interested in peptides, but not the needles?

Peptides marketed for perimenopause and menopause: what is approved and what is not.

What a peptide clinic bill contains, and where safer savings exist.

Nine facts worth knowing about peptides

Peptide medicines are already part of healthcare

One peptide’s results don’t prove another’s

Some peptide medicines come in a capsule

Compounded drugs aren’t FDA approved

One peptide has an approved abdominal-fat use

BPC-157 still has major safety unknowns

A peptide medicine helped reduce fractures

A study headline isn’t the whole story

Peptides aren’t all delivered the same way

Straight answers. A collection you can keep coming back to.

The questions that make peptides easier to understand

What are peptides, in plain English?

Can peptides help with recovery, sleep, skin or energy?

Which peptides do what?

Are peptides safe, and what should I watch out for?

Why do peptide prices vary so much?

Do all peptides involve needles?

What can I realistically expect over time?

Seven big questions. A whole collection of answers.

All 42 guides. Every one included.

What Peptides Actually Are: The Plain-English Map Before You Buy a Vial

Am I Fit for Peptides? Goals, Health History, and "Don't Touch This Yet" Signals

Who Peptides May Help: Recovery, Sleep, Skin, Metabolic, and Performance Buckets

Who Peptides Are Not For: Red Flags to Discuss Before You Start Experimenting

The Peptide Map: BPC-157, TB-500, CJC/Ipamorelin, GHK-Cu, GLP-1s, and What Each Is Supposed to Do

Prescription, Clinic, Compounding Pharmacy, or Research Chemical? The Access Paths Explained

The Evidence Ladder: Which Peptides Have Human Data and Which Are Mostly Hype

The Legal Gray Zone: What "Research Use Only" Really Means for Buyers

The Quality Problem: COAs, Sterility, Storage, and the Ways Bad Vials Burn People

The Peptide Consult Checklist: Questions to Ask Before You Say Yes

Baseline Labs and Health History: What to Know Before Any Peptide Plan

Storage, Handling, and Label Literacy: The Boring Details That Actually Matter

Side Effects and Stop Signals: When to Pause and Call a Professional

Injury and Recovery Peptides: BPC-157, TB-500, and the Claims Around Tissue Repair

Sleep and Growth-Hormone Secretagogues: CJC, Ipamorelin, Tesamorelin, and the Tradeoffs

Skin, Hair, and Copper Peptides: GHK-Cu Without the Beauty-Influencer Fog

Metabolic Peptides: Where GLP-1s Fit and What Else Is Chasing the Same Promise

The Peptide Stack Problem: Why More Compounds Usually Means More Confusion

Cycling, Tolerance, and Breaks: What People Track When Effects Fade

The Results Dashboard: Pain, Sleep, Body Composition, Labs, and Subjective Traps

12 Peptide Myths That Make Beginners Easy to Sell

The Next Peptide Wave: Oral Peptides, Obesity Clinics, Recovery Clinics, and What to Watch

Tendon Pain and Peptide Claims: What BPC-157 and TB-500 Can and Cannot Promise

The Joint-Pain Peptide Pitch: Inflammation, Recovery, and the Evidence Gap

Peptides for Poor Sleep: Recovery Claims, Hormone Tradeoffs, and Better Questions

The Brain-Fog Peptide Guide: Semax, Selank, Focus Claims, and Missing Evidence

Low Energy and Mitochondrial Peptides: MOTS-c, Humanin, and the Hype Check

Skin Aging and Collagen Peptides: GHK-Cu, Topicals, Injections, and Realistic Outcomes

Hair-Loss Peptides: Copper Peptides, Growth Claims, and What Else to Rule Out

The Sexual-Health Peptide Guide: PT-141, Expectations, Side Effects, and Clinical Oversight

Metabolic Plateaus Beyond GLP-1s: Tesamorelin, AOD-9604, and the Clinic-Sales Filter

Gut and Inflammation Peptides: The Claims, the Unknowns, and the Red Flags

Peptides and Low Testosterone: What the Research Shows

Peptides and Immune Support: What the Research Shows

Peptides and Healing After Surgery: What the Research Shows

Peptides and Workout Recovery: What the Research Shows

Peptides, Longevity and Aging: What the Research Shows

Peptides After a GLP-1: What the Research Shows About Keeping Weight Off

Peptides and Back Pain: What the Research Shows

Peptides Without Needles: Oral, Nasal and Topical Routes

Peptides, Perimenopause and Menopause: What the Research Shows

Everything you need to know about peptides, in one collection.
All 42 guides, one place.